
MBX Stock Forecast & Price Target
MBX Analyst Ratings
Bulls say
MBX Biosciences is a clinical stage biotech company focused on developing treatments for endocrine and metabolic disorders using its Precision Endocrine Peptide (PEP) platform. The company's main product candidate, canvuparatide, has shown promising data in Phase 2 trials for hypoparathyroidism (HP) and has the potential for differentiation in convenience, safety, and efficacy compared to other therapies. With a strong pipeline and a healthy cash runway, we believe that MBX has significant potential for success and we maintain our Buy rating.
Bears say
MBX Biosciences is facing potential degradation in efficacy for its pipeline drugs, specifically canvuparatide, due to variations in peak and trough with weekly dosing according to various KOL perspectives, leading to only moderate response rates and potentially making it a less preferred option compared to Yorvipath. This, combined with our calculated risk-adjusted discounted cash flow analysis, leads to our negative outlook on the company's stock as we see limited potential for significant revenues in the long term, with our projected peak revenues for their pipeline drugs at around $2.2B.
This aggregate rating is based on analysts' research of MBX Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
MBX Analyst Forecast & Price Prediction
Start investing in MBX
Order type
Buy in
Order amount
Est. shares
0 shares